2023
International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. Journal Of Urology 2023, 210: 763-770. PMID: 37535836, DOI: 10.1097/ju.0000000000003639.Peer-Reviewed Original ResearchTransurethral resection of bladder tumorResection of bladder tumorNonmuscle-invasive bladder cancerTransurethral resectionBladder tumorsActive surveillanceBladder cancerScoring systemNonmuscle-invasive bladder cancer patientsAbsence of gross hematuriaMultivariate Cox proportional hazards analysisRisk factorsNonmuscle-invasive bladder tumorsNegative urinary cytologyCox proportional hazards analysisMedian follow-upMultivariate Cox regressionBladder cancer patientsProportional hazards analysisUrinary cytologyGross hematuriaT stageLandmark time pointsFollow-upCox regression
2022
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E
Tan W, Bello A, Alvarez C, Guerrero-Ramos F, González-Padilla D, Nzeh C, de la Morena J, de Torres I, Hendricksen K, Goizueta F, Del Álamo J, Chiancone F, Fedelini P, Poggio M, Porpiglia F, Rodríguez V, Torres J, Wilby D, Robinson R, Sousa-Escandón A, Mata J, Moreno J, Molina F, Semino M, Stemberger A, Escudero J, Redorta J, Tan W. A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E. Bladder Cancer 2022, 8: 379-393. PMID: 38994184, PMCID: PMC11181696, DOI: 10.3233/blc-220026.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerTransurethral resection of bladder tumorRecurrence-free survivalProgression-free survivalInvasive bladder cancerMitomycin CBCG-naiveBladder cancerAdverse eventsTreated with intravesical bacillus Calmette-GuerinTreatment of non-muscle invasive bladder cancerIntravesical bacillus Calmette-GuerinResection of bladder tumorTreating non-muscle invasive bladder cancerFavorable adverse event profileAdverse event profileBacillus Calmette-GuerinMinor adverse eventsMulti-institutional studyBCG failurePapillary diseaseTransurethral resectionBladder tumorsConsecutive patientsMedian age